Comparative Pharmacology
Head-to-head clinical analysis: BELDIN versus BENYLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELDIN versus BENYLIN.
BELDIN vs BENYLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
1 capsule (200 mg) orally every 12 hours.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
None Documented
None Documented
Terminal half-life: 8-12 hours (average 10 hours); prolonged in hepatic impairment (up to 24 h) and severe renal impairment (up to 18 h).
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Renal: 30-50% unchanged; hepatic metabolism: 50-70% (CYP3A4); biliary/fecal: 10-20%.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Category C
Category C
Antihistamine
Antihistamine